Exact Sciences: Biomarkers for Treatment Decisions in Early- and Late-stage Prostate Cancer
Steven Canfield, MD

Learning objectives:

1. What are the relevant clinical endpoints (adverse pathology, metastasis, disease-specific death) for risk stratification in early-stage prostate cancer?
2. How do commercial genomic assays for the active surveillance decision compare?
3. How do mpMRI and genomic testing improve risk stratification for early-stage disease?
4. Utilizing the Oncotype DX AR-V7 Nucleus Detect® assay to personalize treatment decisions for mCRPC patients

Watch the full webinar

Astellas: Important Evidence-Based Changes in the Metastatic Castration-Sensitive Prostate Cancer Treatment Landscape
Gordon Brown, DO

Erleada: TITAN and New Data for SPARTAN Final Analysis
Christopher P. Evans, MD, FACS